Bullous Pemphigoid News and Research

RSS

Bullous pemphigoid (BP) is a condition that affects the skin with an autoimmune etiology. It is often seen in those over the age of 80 and the prevalence is even higher in elderly people with neurological comorbidities such as stroke, Parkinson disease and dementia.

Research reveals increased inflammatory activity in patients with frontotemporal dementia

Recent research from the University of Eastern Finland revealed increased inflammatory activity in a subgroup of patients with frontotemporal dementia. Increased inflammation was associated with parkinsonism symptoms and more rapid disease progression.

15 Oct 2019

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Researchers identify risk factor for drug-induced skin disease in diabetic patients

Researchers have identified a type of human leukocyte antigen (HLA) that is associated with the skin disease bullous pemphigoid (BP) in diabetic patients administered with DPP-4 inhibitory drugs.

6 Dec 2017

TxCell, LIED collaborate to develop CAR-Treg-based cellular immunotherapy for bullous pemphigoid

TxCell SA, a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells to treat severe chronic inflammatory and autoimmune diseases, today announces the signature of a strategic R&D collaboration agreement with the Lübeck Institute of Experimental Dermatology, a leading institution in the field of translational research on skin blistering diseases, part of the University of Lübeck in Germany.

2 Jun 2016

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC).

17 Nov 2015

Immune submits Bertilimumab IND application to FDA for treatment of Bullous Pemphigoid

Immune Pharmaceuticals, Inc. announced today that it has submitted an Investigational New Drug Application in the U.S. to expand recruiting for its first in class lead product candidate, Bertilimumab, for the treatment of Bullous Pemphigoid (BP).

7 Oct 2015

Immune Pharmaceuticals begins bertilimumab Phase II clinical trials in Bullous Pemphigoid, Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that it has initiated its Phase II Ulcerative Colitis clinical trial and is scheduled to initiate its Phase II Bullous Pemphigoid clinical trial on July 1, 2015. Study Initiation is the training of hospital staff to allow for patient screening and immediate patient enrollment into the clinical trial upon selection.

25 Jun 2015

Immune Pharmaceuticals announces Q1 2015 financial results; files Quarterly Report on Form 10-Q

Immune Pharmaceuticals Inc. announced financial results for the first quarter ended March 31, 2015. Immune filed its Quarterly Report on Form 10-Q for the first quarter of 2015 on Friday, May 15, 2015.

18 May 2015

iCo Therapeutics announces corporate update and Q3 2014 financial results

iCo Therapeutics ("iCo" or "the Company"), today reported financial results for the nine months ended September 30, 2014. Amounts, unless specified otherwise, are expressed in Canadian dollars and presented under International Financial Reporting Standards ("IFRS").

29 Nov 2014

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune Pharmaceuticals Inc. announces today that it has initiated the screening of patients for a Phase II proof of concept clinical trial exploring the safety and efficacy of bertilimumab in the treatment of ulcerative colitis (UC).

18 Sep 2014

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, the International Pemphigus Pemphigoid Foundation (IPPF) and Immune Pharmaceuticals Inc., announced a collaboration to increase awareness of unmet needs in treating bullous pemphigoid last night at an event attended by more than sixty patients, physicians, scientists and other interested parties.

24 Jul 2014

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Immune Pharmaceuticals Inc. announced today the completion of the merger of Immune Pharmaceuticals Ltd. and EpiCept Corporation.

26 Aug 2013

Vitamin B3 variant reverses effects of fetal alcohol syndrome in mice

A form of vitamin B3 called nicotinamide can reverse the molecular, cellular, and behavioral effects of fetal alcohol syndrome (FAS) in mice, according to a study by physician-scientists at Weill Medical College of Cornell University.

21 Feb 2006